Trials / Unknown
UnknownNCT03230708
Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites
A Phase I/II Clinical Trial Study on Autologous Erythrocytes Derived Microparticles Packaging Methotrexate Peritoneal Perfusion in the Treatment of Malignant Ascites
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Hui ting Xu，MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study makes an observation over the objective response rate of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination in the treatment of malignant ascites. All the participants will randomly receive the treatment of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination or convention drugs peritoneal perfusion and systemic therapy combination.
Detailed description
As a drug carrier, erythrocytes have their own advantages, such as high biocompatibility, high immune compatibility, simple structure and easy access. In this study, microparticles released from erythrocytes are used as the carrier of chemotherapy drugs and effectively kill tumor cells in malignant ascites. These microparticles can easily reach the tumor site and bring the drug into tumor cells, which can overcome the two main problems in normal chemotherapy: damage to normal cells and drug resistance of tumor cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Erythrocytes derived MPs containing MTX | General conventional treatment and peritoneal drainage, additional peritoneal perfusion with erythrocytes derived MPs containing MTX |
| DRUG | convention drugs | according to usage method of drugs |
Timeline
- Start date
- 2017-05-01
- Primary completion
- 2017-12-01
- Completion
- 2018-02-01
- First posted
- 2017-07-26
- Last updated
- 2017-07-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03230708. Inclusion in this directory is not an endorsement.